Attorney Docket No.:

Inventors:

Serial No.:

Filing Date:

Page 2

PTQ-0012

Adams et al.

09/177,711

October 23, 1998

In the Claims:

Please cancel claims 35-40, 45-51 and 53-59.

 \swarrow Please add the following new claims;u

--60. A method of decreasing pain associated with use of prostaglandins for treatment of erectile tissue dysfunction comprising administering to a subject at least one NO producing agent so that pain associated with prostaglandin use sensed by nociceptive tissue in close proximity to engorgeable genital tissue is decreased.

- 61. The method of claim 60 wherein the subject is male.
- 62. The method of claim 60 wherein the subject is female.
- 63. The method of claim 60 wherein the NO producing agent augments action of CAMP in smooth muscle and reduces action of cAMP in nociceptive tissue.
- 64. The method of claim 60 wherein the NO producing agent inhibits a cyclic nucleotide phosphodiesterase.
- 65. The method of claim 64 wherein the cyclic nucleotide phosphodiesterase is PDE3.
- 66. The method of claim 60 wherein the NO producing agent is delivered by a route selected from the group consisting of oral administration, intravenous administration, subcutaneous

0)

Attorney Docket No.:

PTO-0012

Inventors:

Adams et al.

Serial No.: Filing Date:

09/177,711 October 23, 1998

Page 4

The method of claim 70 wherein the subject is male.

72. The method of claim 70 wherein the subject is female.

73. The method of claim 70 wherein the agent augments action of cAMP in smooth muscle and reduces action of cAMP in nociceptive tissue.

74. The method of claim 70 wherein the agent augments action cGMP by generating CO.

75. The method of claim 70 wherein the agent inhibits a cyclic nucleotide phosphodiesterase.

- 76. The method of claim 75 wherein the cyclic nucleotide phosphodiesterase is PDE3.
- 77. The method of claim 70 wherein the agent is delivered by a route selected from the group consisting of oral administration, intravenous administration, subcutaneous administration, inhalation or intranasal administration, transdermal application, topical application, rectal administration, intraurethral administration, and intracavernous introduction.
- · 78. The method of claim 70 wherein two agents are administered.
- 79. The method of claim 70 wherein said agent which augments action of cGMP is selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate,

In the

Attorney Docket No.:

PTQ-0012

Inventors:

Adams et al.

Serial No.:

09/177,711

Filing Date:

October 23, 1998

Page 3

administration, inhalation or intranasal administration, transdermal application, topical application, rectal administration, intraurethral administration, and intracavernous introduction.

- 67. The method of claim 60 wherein two agents are administered.
- 68. The method of claim 60 wherein the NO producing agent is selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine, molsidomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, N-hydroxy-L-arginine, S,S-dinitrosodithiol and NO gas.
- 69. The method of claim 60 wherein the NO producing agent is glyceryl trinitrate.
- 70. A method of decreasing pain associated with use of prostaglandins for treatment of erectile tissue dysfunction comprising administering to a subject at least one agent that augments action of cGMP so that pain associated with prostaglandin use sensed by nociceptive tissue in close proximity to engorgeable genital tissue is decreased.

Sh